Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
6 "Roongroj Bhidayasiri"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson’s Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study
Roongroj Bhidayasiri, Takayuki Ishida, Takanori Kamei, Ryan Edbert Husni, Ippei Suzuki, Shey Lin Wu, Jin Whan Cho
J Mov Disord. 2023;16(2):180-190.   Published online April 26, 2023
DOI: https://doi.org/10.14802/jmd.22196
  • 445 View
  • 95 Download
AbstractAbstract PDFSupplementary Material
Objective
Safinamide is a selective, reversible monoamine oxidase B inhibitor with demonstrated efficacy and tolerability in placebo-controlled studies and is clinically useful for patients with motor fluctuations. This study evaluated the efficacy and safety of safinamide as a levodopa adjunct therapy in Asian patients with Parkinson’s disease.
Methods
Data from 173 Asian and 371 Caucasian patients from the international Phase III SETTLE study were included in this post hoc analysis. The safinamide dose was increased from 50 mg/day to 100 mg/day if no tolerability issues occurred at week 2. The primary outcome was the change from baseline to week 24 in daily ON-time without troublesome dyskinesia (i.e., ON-time). Key secondary outcomes included changes in Unified Parkinson’s Disease Rating Scale (UPDRS) scores.
Results
Safinamide significantly increased daily ON-time relative to placebo in both groups (least-squares mean: 0.83 hours, p = 0.011 [Asians]; 1.05 hours, p < 0.0001 [Caucasians]). Motor function relative to placebo (UPDRS Part III) improved significantly in Asians (-2.65 points, p = 0.012) but not Caucasians (-1.44 points, p = 0.0576). Safinamide did not worsen Dyskinesia Rating Scale scores in either subgroup, regardless of the presence or absence of dyskinesia at baseline. Dyskinesia was largely mild for Asians and moderate for Caucasians. None of the Asian patients experienced adverse events leading to treatment discontinuation.
Conclusion
Safinamide as a levodopa adjunct is well tolerated and effective in reducing motor fluctuations in both Asian and Caucasian patients. Further studies to investigate the real-world effectiveness and safety of safinamide in Asia are warranted.
Umami and Other Taste Perceptions in Patients With Parkinson’s Disease
Priya Jagota, Nattida Chotechuang, Chanawat Anan, Teeraparp Kitjawijit, Chanchai Boonla, Roongroj Bhidayasiri
J Mov Disord. 2022;15(2):115-123.   Published online March 22, 2022
DOI: https://doi.org/10.14802/jmd.21058
  • 2,278 View
  • 186 Download
  • 1 Citations
AbstractAbstract PDF
Objective
Studies of taste perceptions in Parkinson’s disease (PD) patients have been controversial, and none of these studies have assessed umami taste. This study aimed to assess umami, along with the other 4 taste functions in PD patients.
Methods
Participants were tested for gustation using the modified filter paper disc method and olfaction using the modified Sniffin’ Stick-16 (mSS-16) test (only 14 culturally suitable items were used). A questionnaire evaluated patients’ subjective olfactory and gustatory dysfunction, taste preference, appetite, and food habits.
Results
A total of 105 PD patients and 101 age- and sex-matched controls were included. The body mass index (BMI) of PD patients was lower than that of controls (PD = 22.62, controls = 23.86, p = 0.028). The mSS-16 score was 10.7 for controls and 6.4 for PD patients (p < 0.001) (normal ≥ 9). Taste recognition thresholds (RTs) for sweet, salty, sour, bitter and umami tastes were significantly higher in PD, indicating poorer gustation. All taste RTs correlated with each other, except for umami. Most patients were unaware of their dysfunction. Patients preferred sweet, salty and umami tastes more than the controls. Dysgeusia of different tastes in patients was differentially associated with poorer discrimination of tastes, an inability to identify the dish and adding extra seasoning to food. BMI and mSS-16 scores showed no correlation in either patients or controls.
Conclusion
PD patients have dysgeusia for all five tastes, including umami, which affects their appetite and diet. Patients preferred sweet, salty and umami tastes. This information can help adjust patients’ diets to improve their nutritional status.

Citations

Citations to this article as recorded by  
  • Gustatory dysfunction is related to Parkinson's disease: A systematic review and meta‐analysis
    Il‐Youp Kwak, Kyung Soo Kim, Hyun Jin Min
    International Forum of Allergy & Rhinology.2023;[Epub]     CrossRef
Brief communication
Validation of the Thai Version of the Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale
Priya Jagota, Prachaya Srivanitchapoom, Sitthi Petchrutchatachart, Surat Singmaneesakulchai, Apichart Pisarnpong, Praween Lolekha, Suwanna Setthawatcharawanich, Parnsiri Chairangsaris, Natlada Limotai, Pawut Mekawichai, Pattamon Panyakaew, Onanong Phokaewvarangkul, Jirada Sringean, Yuvadee Pitakpatapee, Nancy LaPelle, Pablo Martinez-Martin, Xuehan Ren, Sheng Luo, Glenn T. Stebbins, Christopher G. Goetz, Roongroj Bhidayasiri
J Mov Disord. 2022;15(2):151-155.   Published online March 16, 2022
DOI: https://doi.org/10.14802/jmd.21104
  • 1,963 View
  • 138 Download
  • 2 Citations
AbstractAbstract PDFSupplementary Material
Objective
This study aims to validate the Thai translation of the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS).
Methods
The English version was translated into Thai and then back-translated into English. The translated version underwent 2 rounds of cognitive pretesting to assess the ease of comprehension, ease of use and comfort with the scale. Then, it underwent large clinimetric testing.
Results
The Thai version was validated in 354 PD patients. The comparative fit index (CFI) for all four parts of the Thai version of the MDS-UPDRS was 0.93 or greater. Exploratory factor analysis identified isolated item differences in factor structure between the Thai and English versions.
Conclusion
The overall factor structure of the Thai version was consistent with that of the English version based on the high CFIs (all CFI ≥ 0.90). Hence, it can be designated the official Thai version of the MDS-UPDRS.

Citations

Citations to this article as recorded by  
  • Global Epidemiology of Movement Disorders: Rare or Underdiagnosed?
    Sarah A. O'Shea, Ludy C. Shih
    Seminars in Neurology.2023; 43(01): 004.     CrossRef
  • Vibratory and plantar pressure stimulation: Steps to improve freezing of gait in Parkinson's disease
    Warongporn Phuenpathom, Pattamon Panyakaew, Peerapon Vateekul, Decho Surangsrirat, Akarin Hiransuthikul, Roongroj Bhidayasiri
    Parkinsonism & Related Disorders.2022; 105: 43.     CrossRef
Letter to the editor
Peak-Dose Ballism Associated with Declining Implantable Pulse Generator Battery Life in Deep Brain Stimulation for Parkinson’s Disease
Denzel Chong Jen-Rei, Lim Thien Thien, Lee Hock Keong, Hoe Wei Leng, Onanong Phokaewvarangkul, Roongroj Bhidayasiri
J Mov Disord. 2021;14(2):166-169.   Published online December 7, 2020
DOI: https://doi.org/10.14802/jmd.20078
  • 3,445 View
  • 83 Download
PDFSupplementary Material
Review Article
COVID-19: An Early Review of Its Global Impact and Considerations for Parkinson’s Disease Patient Care
Roongroj Bhidayasiri, Sasivimol Virameteekul, Jong-Min Kim, Pramod Kr. Pal, Sun-Ju Chung
J Mov Disord. 2020;13(2):105-114.   Published online April 30, 2020
DOI: https://doi.org/10.14802/jmd.20042
  • 18,508 View
  • 751 Download
  • 46 Citations
AbstractAbstract PDF
While many infectious disorders are unknown to most neurologists, COVID-19 is very different. It has impacted neurologists and other health care workers, not only in our professional lives but also through the fear and panic within our own families, colleagues, patients and their families, and even in the wider public. COVID-19 affects all sorts of individuals, but the elderly with underlying chronic conditions are particularly at risk of severe disease, or even death. Parkinson’s disease (PD) shares a common profile as an age-dependent degenerative disorder, frequently associated with comorbidities, particularly cardiovascular diseases, so PD patients will almost certainly fall into the high-risk group. Therefore, the aim of this review is to explore the risk of COVID-19 in PD based on the susceptibility to severe disease, its impact on PD disease severity, potential long-term sequelae, and difficulties of PD management during this outbreak, where neurologists face various challenges on how we can maintain effective care for PD patients without exposing them, or ourselves, to the risk of infection. It is less than six months since the identification of the original COVID-19 case on New Year’s Eve 2019, so it is still too early to fully understand the natural history of COVID-19 and the evidence on COVID-19-related PD is scant. Though the possibilities presented are speculative, they are theory-based, and supported by prior evidence from other neurotrophic viruses closely related to SARS-CoV-2. Neurologists should be on high alert and vigilant for potential acute and chronic complications when encountering PD patients who are suspected of having COVID-19.

Citations

Citations to this article as recorded by  
  • Survey on the Impact of the COVID-19 Pandemic on Patients with Parkinson’s Disease and Their Caregivers in Japan
    Nobutaka Hattori, Yoshiko Okada, Yayoi Kawata, Yoshihiko Furusawa, Takumi Imai, Hisako Yoshida, Mihoko Ota, Masaki Arai, Ayumi Shintani, Jovelle Fernandez
    Patient Preference and Adherence.2023; Volume 17: 1221.     CrossRef
  • COVID-19 and neurological disorders: what might connect Parkinson’s disease to SARS-CoV-2 infection
    Salvatore Iacono, Giuseppe Schirò, Chiara Davì, Sergio Mastrilli, Michelle Abbott, Fabrizio Guajana, Valentina Arnao, Paolo Aridon, Paolo Ragonese, Cesare Gagliardo, Claudia Colomba, Nicola Scichilone, Marco D’Amelio
    Frontiers in Neurology.2023;[Epub]     CrossRef
  • Doctor Hope; Calming and Comforting Loneliness in Parkinson’s Disease
    Sasivimol Virameteekul, Roongroj Bhidayasiri
    Clinical Parkinsonism & Related Disorders.2022; 6: 100131.     CrossRef
  • Neurological toll of COVID-19
    Shivam Bhola, Jhillika Trisal, Vikram Thakur, Parneet Kaur, Saurabh Kulshrestha, Shashi Kant Bhatia, Pradeep Kumar
    Neurological Sciences.2022; 43(4): 2171.     CrossRef
  • Resilience and Trauma among Patients with Parkinson’s Disease during the COVID-19 Pandemic
    Roberto Erro, Sofia Cuoco, Emanuele Nigro, Raffaele Ragone, Paolo Barone
    Journal of Movement Disorders.2022; 15(1): 77.     CrossRef
  • Implication of Covid-19 on Neurological Complications with Specific Emphasis on Alzheimer’s and Parkinson’s Disease
    Ankita Sood, Ravi Goyal, Harshdeep Singh, Tapan Behl, Sandeep Arora, Balraj Saini, Rajwinder Kaur
    CNS & Neurological Disorders - Drug Targets.2022; 21(3): 235.     CrossRef
  • The use of amantadine in the prevention of progression and treatment of COVID-19 symptoms in patients infected with the SARS-CoV-2 virus (COV-PREVENT): Study rationale and design
    Konrad Rejdak, Piotr Fiedor, Robert Bonek, Aleksander Goch, Agnieszka Gala-Błądzińska, Waldemar Chełstowski, Jacek Łukasiak, Sławomir Kiciak, Piotr Dąbrowski, Mateusz Dec, Zbigniew J. Król, Ewa Papuć, Adriana Zasybska, Agnieszka Segiet, Paweł Grieb
    Contemporary Clinical Trials.2022; 116: 106755.     CrossRef
  • Neuropathological Aspects of SARS-CoV-2 Infection: Significance for Both Alzheimer’s and Parkinson’s Disease
    Jaime Silva, Felipe Patricio, Aleidy Patricio-Martínez, Gerardo Santos-López, Lilia Cedillo, Yousef Tizabi, Ilhuicamina Daniel Limón
    Frontiers in Neuroscience.2022;[Epub]     CrossRef
  • Online dance classes during the Covid-19 pandemic: new challenges and teaching strategies for the ‘Dance & Parkinson’s at home’ project
    Marcela Dos Santos Delabary, Isadora Loch Sbeghen, Mariana Wolffenbuttel, Djefri Ramon Pereira, Aline Nogueira Haas
    Research in Dance Education.2022; : 1.     CrossRef
  • Impact of the COVID-19 Pandemic on Chronic Neurological Disorders: Focus on Patients with Dementia
    Maria Antonietta Barbieri, Gianluca Bagnato, Carmelo Ioppolo, Antonio Giovanni Versace, Natasha Irrera
    CNS & Neurological Disorders - Drug Targets.2022; 21(10): 1017.     CrossRef
  • COVID-19 and Parkinson’s disease: a systematic review and meta-analysis
    Maryam Afraie, Ghobad Moradi, Pardis Mohammadzedeh, Mobin Azami, Sevda Riyahifar, Yousef Moradi
    Acta Neurologica Belgica.2022;[Epub]     CrossRef
  • Factors Related to Experiencing Pain in Patients Affected by Chronic Inflammatory Rheumatic Disease During the COVID-19 Pandemic
    Tfarah El Joumani, Hanan Rkain, Fatima Zahrae Taik, Kenza Hassouni, Redouane Abouqal, Sara Bahloul, Nada Alami, Latifa Tahiri, Najia Hajjaj-Hassouni, Fadoua Allali
    The Open Pain Journal.2022;[Epub]     CrossRef
  • A “new” role of amantadines in COVID-19 in patients with Parkinson’s disease: results of own comparative study
    Z. A. Zalyalova, S. E. Munasipova, D. M. Khasanova, G. R. Ilyina, Z. G. Khayatova, N. I. Bagdanova
    Neurology, Neuropsychiatry, Psychosomatics.2022; 14(6): 40.     CrossRef
  • Attitudes toward telemedicine of patients with Parkinson’s disease during the COVID‐19 pandemic
    Kanako Kurihara, Koichi Nagaki, Kotoe Inoue, Sumiko Yamamoto, Takayasu Mishima, Shinsuke Fujioka, Shinji Ouma, Yoshio Tsuboi
    Neurology and Clinical Neuroscience.2021; 9(1): 77.     CrossRef
  • Risk of Hospitalization and Death for COVID ‐19 in People with Parkinson's Disease or Parkinsonism
    Luca Vignatelli, Corrado Zenesini, Laura M.B. Belotti, Elisa Baldin, Giuseppe Bonavina, Giovanna Calandra‐Buonaura, Pietro Cortelli, Carlo Descovich, Giovanni Fabbri, Giulia Giannini, Maria Guarino, Roberta Pantieri, Giuseppe Samoggia, Cesa Scaglione, Sus
    Movement Disorders.2021; 36(1): 1.     CrossRef
  • Impact of COVID-19 in the Mental Health in Elderly: Psychological and Biological Updates
    Roberta Eduarda Grolli, Maiqueli Eduarda Dama Mingoti, Amanda Gollo Bertollo, Adriana Remião Luzardo, João Quevedo, Gislaine Zilli Réus, Zuleide Maria Ignácio
    Molecular Neurobiology.2021; 58(5): 1905.     CrossRef
  • COVID-19: Implications for Sudden Death in Parkinson’s Disease
    Ana Claudia Fiorini, Marcelo Cunio Machado Fonseca, Carla Alessandra Scorza, Josef Finsterer, Antônio Márcio Rodrigues, Antônio-Carlos Guimarães de Almeida, Fulvio Alexandre Scorza
    Journal of Movement Disorders.2021; 14(1): 78.     CrossRef
  • Impact and Challenges of the COVID-19 Pandemic on Patients Requiring Botulinum Toxin A Treatment
    Azalea Tenerife Pajo, Adrian Isidoro Espiritu, Roland Dominic Go Jamora
    Journal of Movement Disorders.2021; 14(1): 29.     CrossRef
  • COVID-19 in age-related neurodegenerative diseases: is there a role for vitamin D3 as a possible therapeutic strategy?
    Milena de Barros Viana, Bárbara dos Anjos Rosário, Maria de Fátima Santana de Nazaré, Débora Estadella, Daniel Araki Ribeiro, Glauce Socorro de Barros Viana
    Reviews in the Neurosciences.2021; 32(2): 235.     CrossRef
  • How COVID-19 will boost remote exercise-based treatment in Parkinson’s disease: a narrative review
    Agnes Langer, Lucia Gassner, Anna Flotz, Sebastian Hasenauer, Jakob Gruber, Laurenz Wizany, Rochus Pokan, Walter Maetzler, Heidemarie Zach
    npj Parkinson's Disease.2021;[Epub]     CrossRef
  • Neurological Manifestation of SARS-CoV-2 Induced Inflammation and Possible Therapeutic Strategies Against COVID-19
    Dipak Kumar, Sadaf Jahan, Andleeb Khan, Arif Jamal Siddiqui, Neeru Singh Redhu, Wahajuddin, Johra Khan, Saeed Banwas, Bader Alshehri, Mohammed Alaidarous
    Molecular Neurobiology.2021; 58(7): 3417.     CrossRef
  • Auswirkungen der COVID-19 Pandemie auf die medizinische Versorgung von Patienten mit angeborenen Blutungsneigungen
    Martin Olivieri, Susan Halimeh, Cornelia Wermes, Wolf Hassenpflug, Katharina Holstein, Sylvia von Mackensen
    Das Gesundheitswesen.2021; 83(04): 282.     CrossRef
  • Parkinsonism hyperpyraexia syndrome in Parkinson's disease patients undergoing deep brain stimulation: An indirect consequence of COVID-19 lockdowns
    Onanong Phokaewvarangkul, Sasivimol Virameteekul, Roongroj Bhidayasiri
    Parkinsonism & Related Disorders.2021; 87: 39.     CrossRef
  • Clinical Profiles and Mortality of COVID ‐19 Inpatients with Parkinson's Disease in Germany
    Raphael Scherbaum, Eun Hae Kwon, Daniel Richter, Dirk Bartig, Ralf Gold, Christos Krogias, Lars Tönges
    Movement Disorders.2021; 36(5): 1049.     CrossRef
  • Chronic pain experience and health inequities during the COVID-19 pandemic in Canada: qualitative findings from the chronic pain & COVID-19 pan-Canadian study
    Lise Dassieu, M. Gabrielle Pagé, Anaïs Lacasse, Maude Laflamme, Vickie Perron, Audrée Janelle-Montcalm, Maria Hudspith, Gregg Moor, Kathryn Sutton, James M Thompson, Manon Choinière
    International Journal for Equity in Health.2021;[Epub]     CrossRef
  • The Influence of Coronavirus Disease-2019 (COVID-19) On Parkinson’s Disease: An Updated Systematic Review
    Vikash Jaiswal, Danah Alquraish, Zouina Sarfraz, Azza Sarfraz, Shavy Nagpal, Prakriti Singh Shrestha, Dattatreya Mukherjee, Prathima Guntipalli, Diana F. Sánchez Velazco, Arushee Bhatnagar, Saloni Savani, Elmjedina Halilaj, Samir Ruxmohan, Wilson Cueva
    Journal of Primary Care & Community Health.2021; 12: 215013272110397.     CrossRef
  • Personalized Medicine in Parkinson’s Disease: New Options for Advanced Treatments
    Takayasu Mishima, Shinsuke Fujioka, Takashi Morishita, Tooru Inoue, Yoshio Tsuboi
    Journal of Personalized Medicine.2021; 11(7): 650.     CrossRef
  • Parkinson's disease patients may have higher rates of Covid-19 mortality in Iran
    Mehri Salari, Masoud Etemadifar, Farzad Ashrafi, Davood Ommi, Zahra Aminzade, Sepand Tehrani Fateh
    Parkinsonism & Related Disorders.2021; 89: 90.     CrossRef
  • COVID-19 social distancing: negative effects on people with Parkinson disease and their associations with confidence for self-management
    Galit Yogev-Seligmann, Michal Kafri
    BMC Neurology.2021;[Epub]     CrossRef
  • Covid-19 in Parkinson's Disease treated by drugs or brain stimulation
    M. Salari, M. Etemadifar, A. Zali, Z. Aminzade, I. Navalpotro-Gomez, S. Tehrani Fateh
    Neurología.2021;[Epub]     CrossRef
  • Management of Parkinson’s Disease in the COVID-19 Pandemic and Future Perspectives in the Era of Vaccination
    Yue Hui Lau, Keng Ming Lau, Norlinah Mohamed Ibrahim
    Journal of Movement Disorders.2021; 14(3): 177.     CrossRef
  • Parkinson’s Disease and the COVID-19 Pandemic: A Review Article on the Association between SARS-CoV-2 and α-Synucleinopathy
    Smriti Sinha, Swati Mittal, Rupali Roy
    Journal of Movement Disorders.2021; 14(3): 184.     CrossRef
  • Impact of COVID‐19 on Patient Care, Training, and Research in Movement Disorders in MDS‐AOS Region
    Shweta Prasad, Hrishikesh Kumar, Roongroj Bhidayasiri, Pramod Kumar Pal
    Movement Disorders.2021; 36(11): 2457.     CrossRef
  • Secondary Impact of COVID-19 Pandemic on People with Parkinson’s Disease—Results of a Polish Online Survey
    Karolina Krzysztoń, Beata Mielańczuk-Lubecka, Jakub Stolarski, Anna Poznańska, Katarzyna Kępczyńska, Agata Zdrowowicz, Izabela Domitrz, Jan Kochanowski
    Brain Sciences.2021; 12(1): 26.     CrossRef
  • Neurological consultations and diagnoses in a large, dedicated COVID-19 university hospital
    Adalberto STUDART-NETO, Bruno Fukelmann GUEDES, Raphael de Luca e TUMA, Antonio Edvan CAMELO FILHO, Gabriel Taricani KUBOTA, Bruno Diógenes IEPSEN, Gabriela Pantaleão MOREIRA, Júlia Chartouni RODRIGUES, Maíra Medeiros Honorato FERRARI, Rafael Bernhart CAR
    Arquivos de Neuro-Psiquiatria.2020; 78(8): 494.     CrossRef
  • Potential impact and challenges associated with Parkinson’s disease patient care amidst the COVID-19 global pandemic
    Ali Elbeddini, Anthony To, Yasamin Tayefehchamani, Cindy Wen
    Journal of Clinical Movement Disorders.2020;[Epub]     CrossRef
  • COVID-19 and possible links with Parkinson’s disease and parkinsonism: from bench to bedside
    David Sulzer, Angelo Antonini, Valentina Leta, Anna Nordvig, Richard J. Smeyne, James E. Goldman, Osama Al-Dalahmah, Luigi Zecca, Alessandro Sette, Luigi Bubacco, Olimpia Meucci, Elena Moro, Ashley S. Harms, Yaqian Xu, Stanley Fahn, K. Ray Chaudhuri
    npj Parkinson's Disease.2020;[Epub]     CrossRef
  • Impact of Prolonged Lockdown due to COVID-19 in Patients with Parkinson's Disease
    Shweta Prasad, VikramVenkappayya Holla, Koti Neeraja, BharathKumar Surisetti, Nitish Kamble, Ravi Yadav, PramodKumar Pal
    Neurology India.2020; 68(4): 792.     CrossRef
  • The Effect of the COVID-19 Pandemic on People with Parkinson’s Disease
    Ethan G. Brown, Lana M. Chahine, Samuel M. Goldman, Monica Korell, Emerald Mann, Daniel R. Kinel, Vanessa Arnedo, Kenneth L. Marek, Caroline M. Tanner
    Journal of Parkinson's Disease.2020; 10(4): 1365.     CrossRef
  • Impact of COVID‐19 pandemic on mental health of patients with inherited bleeding disorders in Germany
    Sylvia Mackensen, Susan Halimeh, Manuela Siebert, Cornelia Wermes, Wolf Hassenpflug, Katharina Holstein, Martin Olivieri
    Haemophilia.2020;[Epub]     CrossRef
  • Impact of Coronavirus Disease 2019 Pandemic on Parkinson's Disease: A Cross‐Sectional Survey of 568 Spanish Patients
    Diego Santos‐García, Mila Oreiro, Patricia Pérez, Gemma Fanjul, Jose Manuel Paz González, María José Feal Painceiras, Carlos Cores Bartolomé, Lorena Valdés Aymerich, Carlos García Sancho, Maria del Mar Castellanos Rodrigo
    Movement Disorders.2020; 35(10): 1712.     CrossRef
  • The Impact of COVID ‐19 on Access to Parkinson's Disease Medication
    Julia Ling‐Yu Cheong, Zhao Hang Keith Goh, Connie Marras, Caroline M. Tanner, Meike Kasten, Alastair J. Noyce
    Movement Disorders.2020; 35(12): 2129.     CrossRef
  • Deep Brain Stimulation Battery Exhaustion during the COVID-19 Pandemic: Crisis within a Crisis
    Vikram Venkappayya Holla, Koti Neeraja, Bharath Kumar Surisetti, Shweta Prasad, Nitish Kamble, Dwarakanath Srinivas, Ravi Yadav, Pramod Kumar Pal
    Journal of Movement Disorders.2020; 13(3): 218.     CrossRef
  • Clinical Characteristics of Coronavirus Disease 2019 (COVID-19) among Patients at a Movement Disorders Center
    Joy Antonelle de Marcaida, Jeffrey Lahrmann, Duarte Machado, Lawrence Bluth, Michelle Dagostine, Maria Moro-de Casillas, Elena Bortan, Sulada Kanchana, Mark Alberts
    Geriatrics.2020; 5(3): 54.     CrossRef
  • Update on Neurological Manifestations of SARS-CoV-2
    Hisham Valiuddin, Almir Kalajdzic, James Rosati, Kevin Boehm, Dominique Hill
    Western Journal of Emergency Medicine.2020;[Epub]     CrossRef
  • Effects of COVID-19 Lockdown on Movement Disorders Patients With Deep Brain Stimulation: A Multicenter Survey
    Carla Piano, Francesco Bove, Tommaso Tufo, Isabella Imbimbo, Danilo Genovese, Alessandro Stefani, Massimo Marano, Antonella Peppe, Livia Brusa, Rocco Cerroni, Francesco Motolese, Enrico Di Stasio, Marianna Mazza, Antonio Daniele, Alessandro Olivi, Paolo C
    Frontiers in Neurology.2020;[Epub]     CrossRef
Letter to the editor
Beyond the Classic Segawa Disease, GCH1-Associated Neurodegenerative Parkinsonism: Practical Considerations for Physicians
Jirat Chenbhanich, Jirada Sringean, Roongroj Bhidayasiri
J Mov Disord. 2017;10(2):102-104.   Published online April 18, 2017
DOI: https://doi.org/10.14802/jmd.17009
  • 6,609 View
  • 126 Download
  • 4 Citations
PDF

Citations

Citations to this article as recorded by  
  • Comprehensive Analysis of Familial Parkinsonism Genes in Rapid‐Eye‐Movement Sleep Behavior Disorder
    Kheireddin Mufti, Uladzislau Rudakou, Eric Yu, Lynne Krohn, Jennifer A. Ruskey, Farnaz Asayesh, Sandra B. Laurent, Dan Spiegelman, Isabelle Arnulf, Michele T.M. Hu, Jacques Y. Montplaisir, Jean‐François Gagnon, Alex Desautels, Yves Dauvilliers, Gian Luigi
    Movement Disorders.2021; 36(1): 235.     CrossRef
  • Differences in Drug Pharmacokinetics and Motor Fluctuation in DYT-GCH1
    Gerard Saranza, Anthony E. Lang
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.2021; 48(5): 734.     CrossRef
  • A Compound Heterozygote for GCH1 Mutation Represents a Case of Atypical Dopa-Responsive Dystonia
    Subhajit Giri, Tufan Naiya, Shubhrajit Roy, Gautami Das, Gurusidheshwar M. Wali, Shyamal Kumar Das, Kunal Ray, Jharna Ray
    Journal of Molecular Neuroscience.2019; 68(2): 214.     CrossRef
  • Common and rare GCH1 variants are associated with Parkinson disease
    Uladzislau Rudakou, Bouchra Ouled Amar Bencheikh, Jennifer A. Ruskey, Lynne Krohn, Sandra B. Laurent, Dan Spiegelman, Christopher Liong, Stanley Fahn, Cheryl Waters, Oury Monchi, Edward A. Fon, Yves Dauvilliers, Roy N. Alcalay, Nicolas Dupré, Ziv Gan-Or
    Neurobiology of Aging.2018;[Epub]     CrossRef

JMD : Journal of Movement Disorders